River Plate Biotechnology

River Plate Biotechnology is a clinical-stage biotechnology company focused on developing gene therapies for aggressive brain cancers, particularly glioblastoma multiforme (GBM). The company utilizes a proprietary high-capacity adenoviral (HC-Ad) vector platform, which allows for the delivery of large genetic payloads with reduced toxicity compared to traditional viral vectors. Their lead therapeutic strategy employs a dual-vector approach to deliver Herpes Simplex Virus Type 1 Thymidine Kinase (HSV1-TK) and Fms-like Tyrosine Kinase 3 ligand (Flt3L) directly into the tumor. This combination is designed to kill tumor cells while simultaneously stimulating a robust, long-lasting anti-tumor immune response. Founded by prominent researchers in the field of neuro-oncology, River Plate Biotechnology aims to provide a transformative treatment option for patients with limited therapeutic alternatives.